Peginterferon Alfa-2a

other

Identifier: CI-DRUG-00000462
Entity page: /drug/peginterferon-alfa-2a ↗
Edges: 65

Neighbours: 22 cancers2 genes1 variants10 trials14 approvals
Drawn: 49 of 49 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Peginterferon Alfa-2a approved for …APPROVED_FORderived14 of 14
→ approved for	FDA · US · 2023Efficacy supplement 2023-12-11 (see label) FDA (US) · approved · 2023-12-11 · Efficacy supplement 2023-12-11 (see label)	—	approved	not mapped	1	Regulatory	openfda	open ↗
→ approved for	FDA · US · 2017Efficacy supplement 2017-10-13 (see label) FDA (US) · approved · 2017-10-13 · Efficacy supplement 2017-10-13 (see label)

Peginterferon Alfa-2a predicts response to …PREDICTS_RESPONSE_TO1 of 1
← predicts response to	CALR EXON 9 FRAMESHIFTindel	sensitivity	B	Essential Thrombocythemia	1	Curated	civic	graph →

Peginterferon Alfa-2a predicts response to …PREDICTS_RESPONSE_TO1 of 1

← predicts response to

CALR EXON 9 FRAMESHIFTindel

sensitivity

Essential Thrombocythemia

Curated

Peginterferon Alfa-2a targets …TARGETS2 of 2
→ targets	IFNAR1	—	AGONIST	—	1	Curated	chembl	graph →
→ targets	IFNAR2	—	AGONIST	—	1	Curated	chembl	graph →

Peginterferon Alfa-2a investigated for …INVESTIGATED_FOR14 of 14
→ investigated for	Essential Thrombocythemiahematologic_malignancy	supports	B	Essential Thrombocythemia	1	Curated	civic	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Polycythemia Verahematologic_malignancy	unknown	3	Polycythemia Vera	1	Curated	chembl	graph →
→ investigated for	Essential Thrombocythemiahematologic_malignancy	unknown	3	Essential Thrombocythemia	1	Curated	chembl	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype	unknown	3	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Curated	chembl	graph →
→ investigated for	Primary Myelofibrosishematologic_malignancy	unknown	3	Primary Myelofibrosis	1	Curated	chembl	graph →
→ investigated for	Melanomacancer_family	unknown	3	Melanoma	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	2	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Colon Neoplasmsubtype	unknown	2	Colon Neoplasm	1	Curated	chembl	graph →
→ investigated for	Diffuse Intrinsic Pontine Gliomasubtype	unknown	2	Diffuse Intrinsic Pontine Glioma	1	Curated	chembl	graph →
→ investigated for	Multiple Myelomahematologic_malignancy	unknown	2	Multiple Myeloma	1	Curated	chembl	graph →
→ investigated for	Hepatocellular Carcinomasubtype	unknown	2	Hepatocellular Carcinoma	1	Curated	chembl	graph →
→ investigated for	Kidney Neoplasmsubtype	unknown	1	Kidney Neoplasm	1	Curated	chembl	graph →
→ investigated for	Chronic Lymphocytic Leukemiahematologic_malignancy	unknown	1	Chronic Lymphocytic Leukemia	1	Curated	chembl	graph →

Peginterferon Alfa-2a investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 16show all (up to 200)
→ investigated in trials for	Polycythemia Verahematologic_malignancy 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Polycythemia Vera	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Essential Thrombocythemiahematologic_malignancy 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Essential Thrombocythemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanomacancer_family 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Myeloid Leukemia 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myeloid Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Angiosarcoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Angiosarcoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Childhood Solid Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Childhood Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Hepatocellular Carcinomasubtype 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colon Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colon Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Solid Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasm of Uncertain Malignant Potential 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm of Uncertain Malignant Potential	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Myelofibrosishematologic_malignancy 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Myelofibrosis	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →

Peginterferon Alfa-2a studied in …STUDIED_INderived10 of 18show all (up to 200)
→ studied in	NCT05799612Phase 1 · withdrawn Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma · 18 trials list this drug (0 active)	—	—	Angiosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04798612Phase 2 · unknown Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression · 18 trials list this drug (0 active)	—	—	Malignant Colon Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01387763Phase 3 · completed A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms · 18 trials list this drug (0 active)	—	—	Essential Thrombocythemia,Polycythemia Vera,Primary Myelofibrosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT01821963Phase 3 · terminated Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC) · 18 trials list this drug (0 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT02381379Phase 3 · unknown Malaysia Stop Tyrosine Kinase Inhibitor Trial · 18 trials list this drug (0 active)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT02174172Phase 1 · completed A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors · 18 trials list this drug (0 active)	—	—	Malignant Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02407080Phase 1 · completed Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia · 18 trials list this drug (0 active)	—	—	Essential Thrombocythemia,Polycythemia Vera	1	Observed	clinicaltrials	graph →
→ studied in	NCT01259856Phase 3 · completed Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) · 18 trials list this drug (0 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT03253250Phase 4 · unknown The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection · 18 trials list this drug (0 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT00204529Phase 3 · completed Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB · 18 trials list this drug (0 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths